Japan's RegImmune nails down $9.2M to get its pipeline into the clinic

Tokyo drug developer RegImmune has banked $9.2 million in Series D financing to bankroll early-stage products using the company's immune system-regulating platform. Japan Asia Investment Corporation and Nippon Venture Capital led the round, which will allow RegImmune to advance preclinical candidates for Type 1 diabetes, celiac disease and hemophilia, the company said. Meanwhile, its most advanced treatment, RGI-2001 for graft-versus-host disease, has just begun a Phase II study. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.